Compare POWW & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWW | IKT |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | 81 | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.8M | 220.5M |
| IPO Year | N/A | 2020 |
| Metric | POWW | IKT |
|---|---|---|
| Price | $2.36 | $1.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.40 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 691.6K | 570.6K |
| Earning Date | 02-09-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.56 | N/A |
| Revenue Next Year | $0.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.08 | $1.33 |
| 52 Week High | $2.46 | $2.26 |
| Indicator | POWW | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 74.11 | 63.08 |
| Support Level | $1.94 | $1.63 |
| Resistance Level | N/A | $1.91 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 78.00 | 80.95 |
Outdoor Holding Co Formerly AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.